NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Pharmaceutical Company
News Oct 25, 2007
NanoMaterials Technology ("NMT") has announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.
As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.
"Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance," says Dr Jimmy Yun, the CEO of NMT. NMT's niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.
NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board ("SAB").
"It is a great pleasure and honour for us to have both John and Prof. Neumann joining our SAB. Their addition to our SAB is invaluable as they bring with them broad and in-depth experience in the pharmaceutical industry," says Dr. Yun.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Sciformix Corporation Collaborates with Oracle Health SciencesNews
New collaboration enables faster and more informed drug safety decisions.READ MORE